Results concerning the association of adiponectin gene polymorphisms (single-nucleotide polymorphisms, SNPs) with obesity, type 2 diabetes (T2DM), metabolic disorders and insulin resistance have not lead to definite conclusions. The aim of our study was to investigate a possible association between the À11391G4A and À11377C4G SNPs of adiponectin gene and measure of insulin sensitivity evaluated by the hyperinsulinemic-euglycemic clamp in a group of 'uncomplicated' obese subjects (with no associated comorbidities) (n ¼ 99, mean age 35 years) with a history of obesity lasting at least 10 years. The study of uncomplicated obese subjects, free of possible confounding factors that could interfere with insulin sensitivity, such as pharmacological treatment, provides a good model to assess insulin sensitivity per se. We observed that subjects homozygous for the G allele at locus À11391 had lower M (mg/kg min)/fat-free mass (FFM) index and adiponectin levels compared to subjects with GA þ AA genotypes (P ¼ 0.002 and P ¼ 0.03, respectively) and subjects carrying the À11377G variant had lower M (mg/kg min)/FFM index and adiponectin levels compared to noncarriers (P ¼ 0.003 and P ¼ 0.03, respectively). Our results imply that the two promoter SNPs, À11391G4A and À11377C4G, of the adiponectin gene are associated with a reduced insulin sensitivity evaluated by hyperinsulinemic-euglycemic clamp in obese subjects.
Introduction
The mechanisms underlying insulin resistance are not fully known, but obesity and genetic factors could be good candidates; the role of adipose tissue seems to be of great significance as it is not only the major tissue for energy storage but it is also an active endocrine organ, secreting a variety of proteins that notably influence body metabolism and affect energy and glucose homeostasis. 1 Among these proteins, adiponectin is a recently discovered adipose tissuespecific cytokine that plays a role in modulating insulin sensitivity. In human plasma adiponectin exists as low molecular weight (LMW) hexamers of 180 kDa and high molecular weight (HMW) multimers 4300 kDa. 2 A significant body of evidence links HMW adiponectin to insulin sensitivity and adiponectin appears to modulate insulin sensitivity through an effect of HMW multimers on the liver. 3 Different single-nucleotide polymorphisms (SNPs) identified in the adiponectin gene, were found to be associated with the risk of diseases such as: obesity, insulin resistance, type 2 diabetes (T2DM) and metabolic disorders. [4] [5] [6] [7] [8] However, some studies have failed to detect an association between adiponectin SNPs and derived indexes of insulin resistance such as the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) etc. [8] [9] [10] Several formulae have been developed to assess insulin sensitivity from measurements in the fasting state and during the oral glucose tolerance test (OGTT). The hyperinsulinemic-euglycemic clamp continues to be considered the gold standard method to quantify insulin sensitivity in vivo since it directly measures the effects of insulin to promote glucose utilization under standard conditions. 11 However, the glucose clamp is not used in large clinical or epidemiological studies where simpler methods are required.
In view of these considerations, the aim of our study was to investigate a possible association of the À11391G4A and À11377C4G SNPs of the adiponectin gene with measures of insulin sensitivity evaluated by the hyperinsulinemic-euglycemic clamp in uncomplicated obese subjects (with no associated comorbidities). 12 HOMA-IR index data also were provided to compare our results with those reported in the literature. [8] [9] [10] The study of uncomplicated obese subjects who did not undergo any pharmacological treatment that could interfere with insulin action, reduces possible confounding factors. Hence the search for genetic determinants for obesity and related traits in a phenotypically homogeneous population could increase the chance of finding the responsible loci. , mean age 3579.5) since they did not undergo any treatment known to interfere with insulin sensitivity and metabolic syndrome related parameters (hypolipemic drugs, insulin sensitizers, corticosteroid hormone, acetyl salicilic acid, b-blockers, oral contraceptives, thiazide diuretics, angiotensin 1 converting enzyme-inhibitors). Moreover, these individuals were defined 'uncomplicated' since they had no history of IGT, T2DM, hypertension, dyslipidemia or coronary artery disease. All subjects gave their written informed consent to participate to the study after being informed of its nature. The study protocol was approved by the Ethical Committee of the University 'La Sapienza' in Rome.
Research methods and procedures
All the obese subjects included in the study had normal fasting plasma glucose (o6.1 mmol/l) and underwent an OGTT to assess the normality of their glucose tolerance (2-h plasmatic glucose o7.7 mmol/l). Physical examination showed normal resting arterial blood pressure (systolic o135 mm Hg and diastolic o85 mm Hg in at least three measurements), and a fasting blood sample observed normal serum levels of total cholesterol (o5.18 mmol/l), high-density lipoprotein (HDL) (41.03 mmol/l) triglycerides (o1.69 mmol/l) and normal thyroid hormones. None of the subjects was taking any medication.
The hyperinsulinemic-euglycemic clamp technique
The hyperinsulinemic-euglycemic clamp was performed in all the study subjects. After an overnight fast at 9 h, a polyethylene canula was inserted into an antecubital vein for the infusion. A second catheter was inserted into the antecubitalvein contralateraly to determine plasma glucose and insulin concentrations. Insulin was continuously infused at the rate of 4.0 mU/kg min for 5 min, 2.0 mU/kg min for 110 min. Plasma glucose concentration was measured every 5 min after the start of insulin infusion and a variable infusion of 20% glucose was adjusted, based on the negative feedback principle to maintain the plasma glucose level at fasting plasma glucose with a coefficient of variation o5%. Plasma samples were collected every 20 min for the determination of the insulin concentrations. The steady state of the test was considered the interval between 60 and 120 min. In these standard conditions, glucose infusion requirement in order to maintain euglycemia equals whole body insulin mediated glucose disposal, indicating the degree of insulin sensitivity. Whole body glucose utilization (M index) was calculated from the infusion rate of the exogenous glucose, during the second hour of the insulin clamp period, after correction for changes in glucose levels, in a distribution volume of 250 ml/kg. The M index was adjusted by kilograms of fat-free mass (FFM) obtained by bioimpedance as described in the following paragraph.
13,14
Bioelectrical impedance analyzer Fat mass (FM) and FFM were estimated using a bioelectrical impedance analyser (BIA-103; Akern, Florence, Italy) following the manufacturer's equations, which included data from obese and normal-weight subjects.
Analytical procedure
Cholesterol and triglyceride concentrations were determined in plasma by Technicon RA-1000 Autoanalyzer; HDL was measured after precipitation of ApoB-containing lipoproteins with phosphotungstic acid/MgCl 2 . Low-density lipoprotein (LDL)-cholesterol was determined by the Friedewald formula. 15 Glucose levels were calculated by the glucose oxidase method (Autoanalyzer, Beckman Coulter, USA). Plasma insulin was measured on frozen samples by radioimmunoassay (Adaltis insulin kit, Bologna, Italy), according to the manufacturer's instruction, with a limit of detection of o2.0 mU/ml. 16 Insulin resistance status was also estimated according to HOMA-IR following the formula previously described: 15 fasting insulin (mU/ml) Â fasting glucose (mmol/l)/22.5. Total serum adiponectin was measured using human adiponectin radioimmunoassay (Linco Research Inc, St Charles, MI, USA).
Genotyping of polymorphisms
The À11391 G4A and À11377 C4G SNPs, were genotyped using the flurogenic 5 0 nuclease assay application of the ABI PRISM 7900 HT Sequence Detection System (ABI, foster City, USA). The conditions for TaqMan reaction were as follows: 951C for 10 min, and 35 cycles of 951C 15 s and 601C 1 min.
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Statistical analysis
Statistical analysis was performed using SPSS statistical software, version 13 (SPSS, IL, USA). The genotypic frequencies of the SNPs investigated were in agreement with Hardy-Weinberg equilibrium. The effect of the polymorphisms on quantitative variables was investigated using multiple linear regression analysis. The values were adjusted for BMI, age and gender; each polymorphism was introduced as a dichotomous variable in the analysis.
In addition the interaction between genotypes and sex on insulin sensitivity (M index) was included in the model.
Data for insulin, triglycerides, HOMA-IR and adiponectin levels, were log 10 transformed to normalize their distribution.
We calculated that with the sample size of this study, there is 80% power, to detect a mean difference of E30% in M index significantly at the a ¼ 0.05 level assuming the observed value of the standard deviation. The difference, 30% is that observed previously. 4 
Results
We observed that subjects homozygous for G allele at locus À11391 of adiponectin gene had lower M(mg/kg min)/FFM index and adiponectin levels compared to subjects with GA þ AA genotypes (P ¼ 0.002 and P ¼ 0.03) ( Table 1) and subjects carrying the À11377G variant had lower M(mg/kg min)/FFM index and adiponectin levels compared to noncarriers (P ¼ 0.003 and P ¼ 0.03) ( Table 2 ). The results remain significant after adjusting for BMI, age and sex, even though the two genders were not equally represented in our sample. Furthermore, the correction of the M index for the FFM can also reduce the differences between men and women. The P-value for interaction between genotypes and sex on insulin sensitivity (M index) is not statistically significant (P ¼ 0.9).
No significant differences were observed between these two SNPs and the other investigated parameters.
The linkage disequilibrium between the two polymorphisms (D 0 ¼ 0.7) was similar to that observed in another Caucasian population. 10 
Discussion
This is the first study to analyse and identify an association between the À11391G4A and À11377C4G polymorphisms in the adiponectin gene, and reduced insulin sensitivity evaluated by hyperinsulinemic-euglycemic clamp in obese subjects. Moreover, we found that these genetic variants modulate adiponectin levels.
The use of the clamp appears to be the most appropriate method to assess insulin sensitivity. Indeed, we did not find any statistically significant association between HOMA-IR and the genetic variants even though we recruited only obese subjects who without pharmacological treatment that could interfere with insulin action. The lack of association observed in previous studies and in the present one between the HOMA-IR index and the two genetic variants could be due to the fact that the HOMA-IR index is not a direct measure of insulin resistance but a derived value without the high sensitivity and specificity of the hyperinsulinemic-euglycemic Promoter region of adiponectin gene and insulin sensitivity R Buzzetti et al clamp. These findings confirm the importance of assessing insulin sensitivity in vivo by glucose clamp in a small cohort of people where the use of the HOMA-IR index is less indicated. Consistently with this result, previous studies, investigating the relation between the SNPs of adiponectin gene and parameters of insulin sensitivity by HOMA-IR index, have failed to detect an association. [8] [9] [10] A previous study performed in a French population supported the idea that functional polymorphisms in promoter region (À11391G4A and À11377C4G) of adiponectin gene modulating the level of fat-secreted adiponectin hormone, are associated with adiponectin levels and contribute to the genetic risk for T2DM, even though they failed to detect an association between these two adiponectin SNPs and insulin resistance indexes (assessed by fasting insulin, the ratio of fasting insulinemia to fasting glycemia and the HOMA-S index). 10 Two recent studies, 6, 9 did not find any association between genetic variants of adiponectin gene and insulin sensitivity evaluated by hyperinsulinemic-euglycemic clamp. Stumvoll et al. 6 at first found an association but it lost its statistical significance when adjusted for BMI and percentage body fat (P ¼ 0.13). It is important to notice that in the above studies the authors investigated a different clinical phenotype (a subset of Pima Indian individuals and a data set of normal glucose tolerant individuals, respectively) and that a different set of adiponectin SNPs, was evaluated. Conflicting findings between studies could be due to several factors such as: heterogeneity of the study population (population based, clinical based), phenotype (lean, obese, duration of disease) and linkage disequilibrium between SNPs. In this respect the selection of well characterized patients with long duration of obesity certainly reduces the influence of confounding factors such as pharmacological treatments and obesity related pathologies thus increasing the chance to find responsible loci. Different results could also attributed to true differences in allelic association with disease phenotype in different populations. We observed that subjects carrying the susceptibility genotype for the À11391G4A and À11377C4G have significantly lower serum adiponectin levels; strengthening the hypothesis of a relation between the promoter region and hormone secretion. A few studies demonstrated in different mouse models and in humans a positive correlation between plasma adiponectin concentration and peripheral insulin action. [17] [18] [19] Previous characterization of the human adiponectin promoter reported that the two promoter SNPs evaluated in the present study, are close to a potential regulatory sequence and thus could modulate transcriptional activity. 20, 10, 21 We supposed that these two polymorphisms, or an unknown close functional variant in LD, could decrease adiponectin levels and therefore insulin sensitivity.
Although this study provides novel findings, some limitations have to be underlined. Gender distribution was not equally represented even if the statistical analysis gave the same results after correction for this.
In conclusion our results imply that the À11391G4A and the À11377C4G polymorphisms of the adiponectin gene are associated with reduced insulin sensitivity, evaluated by hyperinsulinemic-euglycemic clamp, in obese subjects.
These polymorphisms may contribute to a genetic susceptibility to insulin resistance in obese patients, allowing the Promoter region of adiponectin gene and insulin sensitivity R Buzzetti et al identification of an important risk factor for metabolic and cardiovascular complications. Indeed, insulin resistant people easily develop complete or partial metabolic syndrome. Finally, the possibility to assess genetic or metabolic factors able to reveal the risk of insulin resistance will be particularly important in obese patients, who have not yet developed any complications of the obesity. These patients will be then precociously invited to perform changes in their lifestyle such as physical exercise and diet, to lose fat mass and to prevent further gain of body weight.
